Alvotech

Update in progress

ALVO (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilars across autoimmune, ophthalmology, bone, and cancer indications. Key products include AVT02, a high‑concentration adalimumab biosimilar; AVT04 (ustekinumab) biosimilar; AVT06 (aflibercept) biosimilar; AVT03 (denosumab) biosimilar; AVT05 (golimumab) biosimilar; AVT16 (vedolizumab) biosimilar; AVT23 (omalizumab) biosimilar; and AVT33 (pembrolizumab) in early development. Founded in 2013, based in Luxembourg.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.65; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.31; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive